题名 | UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma |
作者 | |
发表日期 | 2022-06-14 |
发表期刊 | FRONTIERS IN PHARMACOLOGY 影响因子和分区 |
语种 | 英语 |
原始文献类型 | Article |
关键词 | voxtalisib quantitative methodology pharmacokinetic analysis UPLC-MS MS technology rat plasma |
其他关键词 | DUAL PI3K/MTOR INHIBITOR ; IN-VITRO ; SAFETY ; XL765 |
摘要 | Voxtalisib, is a specific, effective, and reversible dual inhibitor, which inhibits both pan-class I phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). To date, voxtalisib has been studied in trials for melanoma, lymphoma, glioblastoma, breast cancer, and other cancers. In this study, a highly sensitive and rapid ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) technology was applied to the quantitative methodology and pharmacokinetic analysis of voxtalisib in rat plasma. After protein precipitation of the analyte by acetonitrile, the chromatographic separation was performed by gradient elution on an Acquity BEH C18 column (2.1 mm x 50 mm, 1.7 mu m) with acetonitrile (solvent A) and 0.1% formic acid (solvent B) as the mobile phase. In the positive ion mode, the mass transfer detection of the analyte and IS was m/z 270.91 > 242.98 and m/z 572.30 > 246.10, respectively. In the concentration range of 1-2000 ng/ml, a good linear relationship of voxtalisib was successfully established by the UPLC-MS/MS technology, and the lower limit of quantification (LLOQ) of the analyte was identified as 1 ng/ml. Intra-day and inter-day precisions for voxtalisib were 7.5-18.7% and 13.0-16.6%, respectively, and the accuracies were in the ranges of -14.0-2.0% and -7.2-3.1%, respectively. The matrix effect, extraction recovery, carryover and stability of the analyte were all in compliance with the acceptance criteria of bioassays recommended by FDA. Finally, the pharmacokinetic profile of the analyte had been availably studied by the UPLC-MS/MS bio-analytical method after rats were treated by intragastric administration with voxtalisib (5 mg/kg). The results indicated that the UPLC-MS/MS technology can effectively and quickly quantify the analyte, and this method can also be used for the pharmacokinetic study of voxtalisib, which can provide reference for the optimization of clinical drug management in the later period. |
资助项目 | National Key Research and Development Program of China [2020YFC2008301] ; PhD Start-up Funds from The First Affiliated Hospital of Wenzhou Medical University [2022QD23] |
出版者 | FRONTIERS MEDIA SA |
出版地 | LAUSANNE |
ISSN | 1663-9812 |
EISSN | 1663-9812 |
卷号 | 13页码:914733 |
DOI | 10.3389/fphar.2022.914733 |
页数 | 7 |
WOS类目 | Pharmacology & Pharmacy |
WOS研究方向 | Pharmacology & Pharmacy |
WOS记录号 | WOS:000817151300001 |
收录类别 | SCIE ; PUBMED ; SCOPUS |
URL | 查看原文 |
PubMed ID | 35774599 |
SCOPUSEID | 2-s2.0-85133502822 |
通讯作者地址 | [Chen, Lianguo]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China ; [Shao, Liu]Chongqing University Cancer Hospital,Chongqing,China |
Scopus学科分类 | Pharmacology;Pharmacology (medical) |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | https://kms.wmu.edu.cn/handle/3ETUA0LF/154524 |
专题 | 附属第一医院 药学院(分析测试中心)_分子药理研究与教学中心 |
通讯作者 | Shao, Liu; Chen, Lianguo |
作者单位 | 1.The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 2.Institute of Molecular Toxicology and Pharmacology,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,China; 3.Chongqing University Cancer Hospital,Chongqing,China |
第一作者单位 | 附属第一医院; 第一临床医学院(信息与工程学院)、附属第一医院; 药学院(分析测试中心) |
通讯作者单位 | 附属第一医院; 第一临床医学院(信息与工程学院)、附属第一医院 |
第一作者的第一单位 | 附属第一医院 |
推荐引用方式 GB/T 7714 | Li, Qingqing,Liu, Ya-Nan,Wang, Jing,et al. UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma[J]. FRONTIERS IN PHARMACOLOGY,2022,13:914733. |
APA | Li, Qingqing., Liu, Ya-Nan., Wang, Jing., Hu, Yingying., Hu, Jinyu., ... & Chen, Lianguo. (2022). UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma. FRONTIERS IN PHARMACOLOGY, 13, 914733. |
MLA | Li, Qingqing,et al."UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma".FRONTIERS IN PHARMACOLOGY 13(2022):914733. |
条目包含的文件 | 下载所有文件 | |||||
文件名称/大小 | 文献类型 | 版本类型 | 开放类型 | 使用许可 | ||
Voxtalisib-Frontiers(1030KB) | 期刊论文 | 作者接受稿 | 开放获取 | CC BY-NC-SA | 浏览 下载 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论